Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Conjupro Biotherapeutics, Inc.
Conjupro Biotherapeutics, Inc.
PMV Pharmaceuticals, Inc
Kivu Bioscience Inc.
NeoImmuneTech
BeOne Medicines
Monte Rosa Therapeutics, Inc
Eli Lilly and Company
Radiopharm Theranostics, Ltd
NiKang Therapeutics, Inc.
MacroGenics
AstraZeneca
SystImmune Inc.
SN BioScience
Boundless Bio, Inc.
Radiopharm Theranostics, Ltd
AbbVie
Janux Therapeutics
NiKang Therapeutics, Inc.
Incyte Corporation
A2 Biotherapeutics Inc.
TransThera Sciences (Nanjing), Inc.
Klus Pharma Inc.
Theratechnologies
Cybrexa Therapeutics
Sotio Biotech Inc.
Cyteir Therapeutics, Inc.
Carisma Therapeutics Inc
Tasly Biopharmaceuticals Co., Ltd.
Travera Inc
Sellas Life Sciences Group
Vincerx Pharma, Inc.
AstraZeneca
Salubris Biotherapeutics Inc
Rhizen Pharmaceuticals SA
Xencor, Inc.
TransThera Sciences (Nanjing), Inc.
Exelixis
HiberCell, Inc.
Shanghai Yunying Medical Technology
Fate Therapeutics
Xencor, Inc.
Xencor, Inc.
Incyte Corporation
Ipsen
AbbVie
AbbVie
Bayer
Incyte Corporation
Gilead Sciences
SpeciCare